vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Sinclair, Inc. (SBGI). Click either name above to swap in a different company.
Sinclair, Inc. is the larger business by last-quarter revenue ($807.0M vs $156.4M, roughly 5.2× BIOCRYST PHARMACEUTICALS INC). On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (7.5% vs 4.0%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs -1.3%).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Sinclair, Inc., doing business as Sinclair Broadcast Group, is a publicly traded American telecommunications conglomerate that is controlled by the descendants of company founder Julian Sinclair Smith. Headquartered in the Baltimore suburb of Cockeysville, Maryland, the company is the second-largest television station operator in the United States by number of stations after Nexstar Media Group, owning or operating 193 stations across the country in over 100 markets, covering 40% of American ...
BCRX vs SBGI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $807.0M |
| Net Profit | — | $20.0M |
| Gross Margin | — | — |
| Operating Margin | 13.6% | 0.0% |
| Net Margin | — | 2.5% |
| Revenue YoY | 7.5% | 4.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | $807.0M | ||
| Q4 25 | $406.6M | $836.0M | ||
| Q3 25 | $159.4M | $773.0M | ||
| Q2 25 | $163.4M | $784.0M | ||
| Q1 25 | $145.5M | $776.0M | ||
| Q4 24 | $131.5M | $1.0B | ||
| Q3 24 | $117.1M | $917.0M | ||
| Q2 24 | $109.3M | $829.0M |
| Q1 26 | — | $20.0M | ||
| Q4 25 | $245.8M | $109.0M | ||
| Q3 25 | $12.9M | $-1.0M | ||
| Q2 25 | $5.1M | $-64.0M | ||
| Q1 25 | $32.0K | $-156.0M | ||
| Q4 24 | $-26.8M | $176.0M | ||
| Q3 24 | $-14.0M | $94.0M | ||
| Q2 24 | $-12.7M | $17.0M |
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — |
| Q1 26 | 13.6% | 0.0% | ||
| Q4 25 | 64.0% | 9.6% | ||
| Q3 25 | 18.6% | 7.5% | ||
| Q2 25 | 18.2% | 2.7% | ||
| Q1 25 | 14.6% | 1.8% | ||
| Q4 24 | -3.4% | 26.5% | ||
| Q3 24 | 6.6% | 19.5% | ||
| Q2 24 | 8.0% | 7.7% |
| Q1 26 | — | 2.5% | ||
| Q4 25 | 60.5% | 13.0% | ||
| Q3 25 | 8.1% | -0.1% | ||
| Q2 25 | 3.1% | -8.2% | ||
| Q1 25 | 0.0% | -20.1% | ||
| Q4 24 | -20.4% | 17.5% | ||
| Q3 24 | -12.0% | 10.3% | ||
| Q2 24 | -11.6% | 2.1% |
| Q1 26 | $0.00 | $0.28 | ||
| Q4 25 | $1.13 | $1.62 | ||
| Q3 25 | $0.06 | $-0.02 | ||
| Q2 25 | $0.02 | $-0.91 | ||
| Q1 25 | $0.00 | $-2.30 | ||
| Q4 24 | $-0.13 | $2.64 | ||
| Q3 24 | $-0.07 | $1.43 | ||
| Q2 24 | $-0.06 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $465.1M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $866.0M | ||
| Q3 25 | $212.9M | $526.0M | ||
| Q2 25 | $260.0M | $616.0M | ||
| Q1 25 | $295.1M | $631.0M | ||
| Q4 24 | $320.9M | $697.0M | ||
| Q3 24 | $96.8M | $536.0M | ||
| Q2 24 | $78.4M | $378.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $4.4B | ||
| Q3 25 | — | $4.1B | ||
| Q2 25 | — | $4.1B | ||
| Q1 25 | — | $4.2B | ||
| Q4 24 | — | $4.1B | ||
| Q3 24 | — | $4.1B | ||
| Q2 24 | — | $4.1B |
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $443.0M | ||
| Q3 25 | $-387.9M | $347.0M | ||
| Q2 25 | $-421.6M | $361.0M | ||
| Q1 25 | $-451.9M | $436.0M | ||
| Q4 24 | $-475.9M | $583.0M | ||
| Q3 24 | $-468.6M | $415.0M | ||
| Q2 24 | $-475.6M | $340.0M |
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $5.9B | ||
| Q3 25 | $446.4M | $5.6B | ||
| Q2 25 | $457.2M | $5.7B | ||
| Q1 25 | $480.0M | $5.8B | ||
| Q4 24 | $490.4M | $5.9B | ||
| Q3 24 | $491.3M | $5.8B | ||
| Q2 24 | $472.4M | $5.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.84× | ||
| Q3 25 | — | 11.75× | ||
| Q2 25 | — | 11.30× | ||
| Q1 25 | — | 9.56× | ||
| Q4 24 | — | 7.02× | ||
| Q3 24 | — | 9.86× | ||
| Q2 24 | — | 12.08× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
SBGI
| Media revenue | $701.0M | 87% |
| Other | $82.0M | 10% |
| Political advertising revenue | $18.0M | 2% |
| Non-media revenue | $6.0M | 1% |
